Clinical trials: Stem Cell Mobilization
Coronary Artery Disease, Atherosclerosis
Rilonacept to Improve Artery Function in Patients With Atherosclerosis
This study will determine whether an experimental drug called Rilonacept can improve artery function in patients with atherosclerosis, a disease in which fatty deposits in arteries cause the vessels to stiffen, impeding blood…
- Conditions
- Coronary Artery Disease, Atherosclerosis, Inflammation, Endothelial Dysfunction
- Trial name
- NCT00417417
- Testing
- Rilonacept
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Multiple Myeloma, Lymphoma
Trial of an Augmented Mobilization Strategy With Plerixafor (Mozobil®) in a Population at Risk for Poor Stem Cell Mobilization
Poor mobilization of hematopoietic progenitors needed to support autologous transplantation is a serious clinical problem. We are investigating the role of plerixafor administered in an at risk population to augment successful…
- Trial name
- NCT01037517
- Testing
- Plerixafor, Observation: Nonintervention
- Where
- Canada
- Volunteers
- 52 people
- Sponsor
- CancerCare Manitoba
HIV Infections
A Study of Stem Cells and Filgrastim
To determine the safety of stem cell harvesting after administration of filgrastim ( G-CSF ) to mobilize bone marrow stem cells into the peripheral blood in patients at various stages of HIV-1 infection as well as in HIV-negative…
- Trial name
- NCT00001071
- Testing
- Filgrastim
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multiple Myeloma, Bone Marrow Transplant Complications
Observational Study to Evaluate Hematopoietic Progenitor Cell Mobilization in Patients With Newly Diagnosed Multiple Myeloma
Prospective, multicenter, observational registry of myeloma patients undergoing hematopoietic progenitor cell mobilization for upfront autologous transplantation.
- Trial name
- NCT03200626
- Testing
- Autologous hematopoietic cell transplant
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- Medical College of Wisconsin
Myocardial Ischemia
ACT34-CMI -- Adult Autologous CD34+ Stem Cells (Follow-Up Study)
The purpose of this 12-month, observational, follow-up study is to collect additional data (by telephone contact) with which to assess the efficacy, safety, and effects of intramyocardial injections of adult autologous CD34+…
- Trial name
- NCT00545610
- Where
- 23 sites in United States
- Volunteers
- 150 people
- Sponsor
- Lisata Therapeutics, Inc.
Graft vs Host Disease, Hematologic Neoplasms
HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malignancies
Many patients with hematological malignancies potentially curable by bone marrow transplantation are not considered for transplantation because an HLA identical family or unrelated donor is unavailable.
- Conditions
- Graft vs Host Disease, Hematologic Neoplasms, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00001748
- Testing
- Peripheral blood progenitor cell transplant
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma
This phase II trial is studying how well giving bendamustine hydrochloride, etoposide, dexamethasone, and filgrastim together for peripheral stem cell mobilization works in treating patients with refractory or recurrent lymphoma…
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
- Trial name
- NCT01110135
- Testing
- bendamustine hydrochloride, dexamethasone, filgrastim
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of Washington
Severe Combined Immunodeficiency
Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim
The goal of this study is to develop a novel approach to hematopoietic stem cell transplantation for children with Severe Combined Immunodeficiency Disease (SCID) that eliminates the use of toxic chemotherapy conditioning and…
- Trial name
- NCT01182675
- Testing
- Transplant Conditioning with Mobilization Only, Transplant Conditioning with Mobilization and Alemtuzumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, San Francisco
Hematologic Malignancies
Feasibility and Cost Analysis of PBSC Mobilization Using Pegfilgrastim in Hematologic Malignancies
The purpose of this study is to determine the efficacy of Pegfilgrastim in the mobilization of autologous peripheral blood stem cells (PBSCs), defined as cell yield ≥ 3 x 10e6 CD34+/kg and to assess the costs related to…
- Trial name
- NCT00689884
- Testing
- Pegfilgrastim
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Acute Lymphoid Leukemia, Acute Myeloid Leukemia
Prophylactic DLI-X for Leukemia Relapse After HCT
The primary objective of this proposal is to conduct the first-in-human randomized clinical trial evaluating prophylactic DLI-X (pro-DLI-X) for relapse prevention following matched sibling donor (MSD) or haploidentical (haplo)…
- Conditions
- Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia (AUL), Myelodysplastic Syndrome
- Trial name
- NCT07254793
- Testing
- Exercise Mobilized Prophylactic DLI, Standard Prophylactic DLI
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- University of Arizona
Healthy Subjects
Feasibility of Thioridazine as a Mobilizing Agent for CD34+ Hematopoietic Progenitor Cells
This study will investigate the possibility of using the drug thioridazine (also called Mellaril) to increase the number of certain types of cells moving from the bone marrow to the circulation in a group of healthy humans.
- Trial name
- NCT01765803
- Testing
- Mellaril
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- New Mexico Cancer Research Alliance
Hematologic Neoplasms
National Marrow Donor Program Long-Term Donor Follow-Up
This is an observational study of unstimulated bone marrow (BM) and filgrastim-mobilized peripheral blood stem cell (PBSC) donors.
- Trial name
- LTDFU (NCT01362179)
- Where
- 29 sites in United States, Puerto Rico
- Volunteers
- 21,974 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Leukemia
Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell or bone marrow transplantation may be able to replace immune cells that were destroyed…
- Trial name
- NCT00002789
- Testing
- busulfan, cyclophosphamide, cyclosporine
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Myeloid Leukemia, Graft vs Host Disease
Modified Bone Marrow Stem Cell Transplantation for Chronic Myelogenous Leukemia
This study will investigate the safety and effectiveness of a new stem cell transplant procedure for treating chronic myelogenous leukemia (CML).
- Trial name
- NCT00001144
- Testing
- Modified bone marrow stem cell transplantation
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hemorrhagic Stroke
The Effect of Early Mobilization in Mild to Moderate Hemorrhagic Stroke
This study aims to examine the outcomes of early mobilization and early intervention within 24-72 hours after the onset of hemorrhagic stroke in patients admitted to an intensive care unit within 24 hours after stroke.
- Trial name
- NCT03292211
- Testing
- early mobilization, early standard intervention
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- National Taiwan University Hospital
Multiple Myeloma
First Line Treatment Trial in Multiple Myeloma, Finnish Myeloma Group- Multiple Myeloma 02
The purpose of this study is to determinate the efficacy and safety of the 3-drug induction treatment (RVD; lenalidomide plus bortezomib plus dexamethasone)followed by randomized autologous stem cell mobilization, autologous stem…
- Trial name
- FMG-MM02 (NCT01790737)
- Testing
- Cyclophosphamide, Filgrastim
- Where
- 12 sites in Finland
- Volunteers
- 80 people
- Sponsor
- Kuopio University Hospital
Chronic Granulomatous Disease
Stem Cell Transplant Following Low-Intensity Chemotherapy to Treat Chronic Granulomatous Disease
This study will investigate the safety and effectiveness of a modified stem cell transplant procedure for treating chronic granulomatous disease (CGD) in patients with active infection.
- Trial name
- NCT00001765
- Testing
- Nexell Isolex with T-cell Depletion, Baxter isolex 300i
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acute Coronary Syndromes
Prognostic Value of Biomarkers Associated With Endothelial Progenitor Cells Mobilization in Acute Coronary Syndromes
This prospective study aimed to validate a new prognostic approach of endothelial progenitor cells associated biomarkers in patients with acute coronary syndromes .
- Trial name
- NCT02117037
- Testing
- blood sample
- Where
- France
- Volunteers
- 180 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Sickle Cell Disease, Thalassemia
Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure
Background: Some sickle cell disease or beta-thalassemia can be cured with transplant. Researchers want to test a variation of transplant that uses low dose radiation and a combination of immunosuppressive drugs.
- Conditions
- Sickle Cell Disease, Thalassemia, Stem Cell Transplantation, Graft vs Host Disease
- Trial name
- NCT02105766
- Testing
- Alemtuzumab, Sirolimus, Cyclophosphamide
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Chromosome Aberrations
Study on the Impact of Stem Cell Donation and Bone Marrow Harvesting on Unrelated Donors
Granulocyte Colony Stimulating Factor (GCSF) is used extensively as a means of mobilising donor peripheral blood stem cells as an alternative to bone marrow harvesting for the purpose of recipient stem cell transplantation.
- Trial name
- NCT01884610
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University College, London